Asked by: Stuart Andrew (Conservative - Daventry)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 2 December 2025 to Question 93697, whether he has made an estimate of the differences in the number of conditions screened for in newborns between the UK and other countries such as Norway, Australia, Italy, Poland, and the Netherlands; and how those differences relate to the internationally recognised criteria used by the UK National Screening Committee.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Screening programmes in the United Kingdom have a more rigorous approach towards evaluating the benefits and harms of screening compared to many other countries such as the United States of America and Italy.
The independent UK National Screening Committee (UK NSC), which is made up of leading medical and screening experts, advises Ministers in all four nations of the UK on the evidence on screening. Where the Committee is confident that screening provides more good than harm, they recommend a screening programme.
Some countries often cited as screening more conditions than the UK are not always running national programmes. Some countries or regions screen for a condition when it is only at the pilot or research stage. Some ‘screening programmes’ just test for a condition rather than being end-to-end quality-assured programmes that include diagnosis, treatment and care. And screening in some countries is delivered regionally, or even just by individual hospitals, rather than nationally. They are therefore not directly comparable to the national screening programmes offered in the UK.
Asked by: Stuart Andrew (Conservative - Daventry)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 2 December 2025 to Question 93697, if he will meet with representatives of ArchAngel MLD Trust, the MPS Society, MLD Support UK, the LSD Collaborative, and Alex – The Leukodystrophy Charity before responding to the UK National Screening Committee’s forthcoming recommendation on Metachromatic Leukodystrophy.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
My rt. Hon. Friend, the Secretary of State for Health and Social Care, will carefully consider a UK National Screening Committee (UK NSC) recommendation on metachromatic leukodystrophy when it is presented to him, before making a decision. The Secretary of State will ask officials to meet with representatives of ArchAngel MLD Trust, the MPS Society, MLD Support UK, the LSD Collaborative, and Alex – The Leukodystrophy Charity.
Asked by: Stuart Andrew (Conservative - Daventry)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential impact of NHS policies on private access for patients with Postural Orthostatic Tachycardia Syndrome seeking faster access to specialist care.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Postural orthostatic tachycardia syndrome (PoTS) is diagnosed by a combination of general practitioners (GPs) and specialist clinicians. GPs can diagnose PoTS in many cases but, if they are unsure of symptoms or if symptoms are complex, they will refer patients to specialists for diagnosis, or where patients do not respond to initial treatment, patients may be referred to specialised cardiology or neurology services. The Royal College of General Practitioners’ Syncope Toolkit provides information to GPs, including the use of the active stand test, to rule out other conditions and potentially diagnose PoTS more quickly. Management of PoTS typically involves lifestyle changes and medications to help control symptoms, and can involve support from a multidisciplinary team.
Where patients are referred to secondary care for diagnosis, we are investing in additional capacity to deliver appointments to help bring waiting lists and times down. The Elective Reform Plan, published in January 2025, sets out the specific productivity and reform efforts needed to return to the constitutional standard, that 92% of patients to wait no longer than 18 weeks from referral to treatment, by March 2029.
By expanding community-based services for routine monitoring and follow up, employing artificial intelligence for productivity, and investing in digital tools and data, as outlined in the 10-Year Health Plan, we can ensure that consultants’ time is reserved for complex cases of PoTS, including specialist diagnostic assessments.
Integrated care boards (ICBs), with oversight from NHS England, have a statutory responsibility to commission services which meet the needs of their local populations, including for those with PoTS. It is the responsibility of ICBs to work with clinicians, service users, and patient groups to develop services and care pathways that meet the needs of patients with PoTS. While the Department recognises the significant challenges of PoTS diagnoses, responsibility for specific clinical pathways and specialist training rests with local National Health Service bodies.
The Department has made no assessment of the impact of NHS policies on private access for patients with PoTS seeking faster access to specialist care.
Asked by: Stuart Andrew (Conservative - Daventry)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to involve cancer charities in the delivery and governance of the forthcoming National Cancer Plan.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Cancer Plan will build on the shift from hospital to community set out by the 10-Year Health Plan and will seek to foster improved collaboration with the voluntary and community sector to deliver this.
Governance mechanisms for monitoring implementation and ensuring accountability for delivery will be established as part of the development of the National Cancer Plan, which will be published in the new year.
Asked by: Stuart Andrew (Conservative - Daventry)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 2 December 2025 to Question 93697, what the average time taken was by the UK National Screening Committee to evaluate proposals for additions to the newborn screening programme; and what steps he is taking to reduce the time taken for decision-making on rare disease screening.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The process from a proposal to screen newborns for a condition, to a decision whether to roll out a national screening programme is multi staged, and the time taken will vary from one condition to the next. This includes procuring evidence products, securing funding, decision on whether to proceed to another evidence product, modelling if required, and evaluation in the National Health Service if needed.
The time for assessment depends entirely on the amount of evidence available and the ability of the screening team to commission and receive evidence reviews. A routine assessment for screening for a new bloodspot condition can take anything from a few months from an open call request to a published evidence map through to one to two years if there is evidence and modelling is required.
A recent example is the implementation of screening for tyrosinaemia in the NHS Newborn Blood Spot Screening Programme, where work began over five years ago. Another example is newborn screening for spinal muscular atrophy where planning for an in-service evaluation is ongoing, and the first evidence review was over seven years ago.
The United Kingdom is not an outlier in terms of the time between first consideration of a proposal to roll out of a programme. France and The Netherlands are estimated to take approximately 10 years.
Reviewing the case for screening for rare conditions can be difficult due to a lack of good quality evidence. The UK National Screening Committee has started to use disease, clinical effectiveness and cost effectiveness modelling to estimate the effects of screening and inform its recommendations, including its recent recommendation to introduce newborn screening for tyrosinaemia.
Asked by: Stuart Andrew (Conservative - Daventry)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the National Cancer Plan will include measures to improve cancer research capacity in hospitals in the North of England.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Research is crucial in tackling cancer, which is why the Department invests over £1.6 billion per year in research through the National Institute for Health and Care Research (NIHR). Cancer is a major area of NIHR spending at £141.6 million in 2024/25, reflecting its high priority. Research is a key focus of the National Cancer Plan. The plan will seek to ensure advances in cancer research benefit patients across the country, including the North of England.
The Department is committed to funding health and care research via the NIHR across England, to ensure that the research we support is inclusive and representative of the populations we serve.
NIHR research infrastructure has national coverage across the whole of England across all geographies and settings. Our infrastructure schemes aim to build research capacity and capability across the country across all geographies and settings. In line with prior commitments, the Department has increased funding for research infrastructure schemes delivering cancer research in northern regions, including Biomedical Research Centres, Clinical Research Facilities, and HealthTech Research Centres.
Through the NIHR Research Delivery Network, the NIHR provides funding and support to the National Health Service and other providers to deliver research, operating across 12 regions throughout the country. The North West, North East and North Cumbria, and Yorkshire and Humber Regional Research Delivery Networks operate in all NHS trusts that span the north of England, giving researchers and delivery teams the practical support they need locally so that more research can take place, and more people can take part.
Asked by: Stuart Andrew (Conservative - Daventry)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what consideration he has given to including prehabilitation and rehabilitation as core elements of cancer treatment in the forthcoming National Cancer Plan.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is working with NHS England to support local systems to deliver effective rehabilitation and prehabilitation services. The National Cancer Plan will aim to improve how the physical and psychosocial needs of people with cancer can be met, with a focus on personalised care to improve quality of life. It will address how the experience of care can be improved for those diagnosed, treated, and living with and beyond cancer.
Asked by: Stuart Andrew (Conservative - Daventry)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 2 December 2025 to Question 93697, whether he has made an estimate of the number of (a) preventable deaths and (b) cases of irreversible disability in children with Metachromatic Leukodystrophy over the last ten years; and how such outcomes are considered in UK National Screening Committee evaluations.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
When evaluating the evidence relating to a health condition such as metachromatic leukodystrophy (MLD), the UK National Screening Committee (UK NSC) considers important issues relating to the condition, the test, the treatment and the effectiveness of a screening programme. Considerations of the condition include reviewing the evidence of its frequency and/or severity, prevalence and incidence.
My rt. Hon. Friend, the Secretary of State for Health and Social Care, is advised by the UK NSC on the evidence on screening. The Committee, which is independent and made up of leading medical and screening experts, advises Ministers in all four nations of the United Kingdom. Where the Committee is confident that screening provides more good than harm, they recommend a screening programme.
Asked by: Stuart Andrew (Conservative - Daventry)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of not extending Start for Life funding to all councils delivering Best Start Family Hubs on (i) the developmental domains assessed in the Early Years Foundation Stage profile and (ii) the government’s commitment to shift from treatment to prevention.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
We are committed to delivering the 10-Year Health Plan ambition to match Healthy Babies, formerly Start for Life, to Best Start Family Hubs over the next decade.
There is strong evidence that the 1,001 days from pregnancy to the age of two years old set the foundations for our cognitive, emotional, and physical development. Supporting babies and their families in this period provides an opportunity to improve health and education outcomes and reduce inequalities, including on Early Years Foundation Stage domains.
We have already started to deliver the shift from treatment to prevention by providing funding to 75 areas to deliver universal, prevention-focussed Healthy Babies services. From April, the Government is rolling out Best Start Family Hubs to all local authorities, backed by over £500 million to reach up to half a million more children and families. This funding will help embed hubs within a wider support system, including integrated child health services, and will enable proactive identification and support for health issues and early developmental delays.
Asked by: Stuart Andrew (Conservative - Daventry)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact on child development outcomes of not matching Start for Life funding with the expansion of Best Start Family Hubs.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
We are committed to delivering the 10-Year Health Plan ambition to match Healthy Babies, formerly Start for Life, to Best Start Family Hubs over the next decade.
There is strong evidence that the 1,001 days from pregnancy to the age of two years old set the foundations for our cognitive, emotional, and physical development. Supporting babies and their families in this period provides an opportunity to improve health and education outcomes and reduce inequalities, including on Early Years Foundation Stage domains.
We have already started to deliver the shift from treatment to prevention by providing funding to 75 areas to deliver universal, prevention-focussed Healthy Babies services. From April, the Government is rolling out Best Start Family Hubs to all local authorities, backed by over £500 million to reach up to half a million more children and families. This funding will help embed hubs within a wider support system, including integrated child health services, and will enable proactive identification and support for health issues and early developmental delays.